Biotech company Regeneron (NASDAQ: REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.
Regeneron beat analysts’ revenue expectations by 11.3% last quarter, reporting revenues of $3.68 billion, up 3.6% year on year. It was an incredible quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.
Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Regeneron’s revenue to decline 4% year on year to $3.57 billion, a reversal from the 10.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $9.61 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Regeneron has missed Wall Street’s revenue estimates twice over the last two years.
With Regeneron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 7.6% on average over the last month. Regeneron is up 3.4% during the same time and is heading into earnings with an average analyst price target of $725.05 (compared to the current share price of $580).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
